AOD9604 (Fragment 176-191): mechanism of action
AOD9604 is the synthetic C-terminal fragment of human growth hormone, spanning residues 176-191. This page sets out what the published literature reports about its mechanism of action, its metabolic and musculoskeletal m
AOD9604 (Fragment 176-191), also written AOD-9604 and hGH 176-191, is a synthetic peptide corresponding to the C-terminal region of human growth hormone, residues 176 through 191. It is classed in the literature among the growth hormone fragment peptides, a subgroup of the agents marketed as research compounds for modulation of the GH-IGF-1 axis [1]. The same review literature lists it under the expanded name Anti-Obesity Drug 9604, reflecting the metabolic direction of the original work [2][3]. The evidence block supplied for this page does not give a residue sequence, molecular formula or molecular weight, so none are stated here.
The work on this fragment centres on the GH-IGF-1 axis and on the lipolytic and metabolic signalling attributed to the 176-191 region of the growth hormone molecule, rather than on the growth-promoting signalling associated with the full-length hormone [1].
Research Studies
AOD9604 and its classification within the GH-IGF-1 axis literature
Reviews of performance-enhancing peptides that modulate the GH-IGF-1 axis place AOD9604 alongside GHRH analogues such as sermorelin, tesamorelin and the CJC-1295 variants, and alongside the growth hormone secretagogues GHRP-2, GHRP-6, hexarelin and ipamorelin [1]. Within that grouping, the fragment is treated as a distinct category rather than as a secretagogue: it is not described as acting through the GHRH receptor or through the ghrelin-receptor secretagogue route, but as a fragment of growth hormone itself [1]. The same review notes that these peptides are marketed as research compounds and are encountered both in clinical practice and in online self-administration protocols, a framing that is relevant to how the published record should be read [1].
AOD9604 and the regulatory status of unapproved peptides
A separate review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describes a parallel gray market of compounds operating largely outside regulatory oversight, and names AOD-9604 among the unapproved peptides marketed direct to patients [2][3]. That review frames peptides generally as occupying a pharmacological niche between small-molecule drugs and large proteins, and contrasts rigorously evaluated approved products with the unapproved segment [2][3]. The regulatory position is therefore part of the mechanism story only in the sense that it defines the quality and quantity of evidence available: for AOD9604 the human dataset is thin relative to the approved comparators in the same reviews [2][3].
AOD9604 and the metabolic and lipolytic model
The name Anti-Obesity Drug 9604 under which the fragment appears in the review literature points to the metabolic and lipolytic direction of the original research programme [2][3]. The GH-IGF-1 axis review treats the fragment as one of the agents intended to modulate that axis, distinct from the secretagogues that act upstream at the pituitary [1]. The evidence block does not supply primary metabolic trial data, effect sizes, or a stated receptor, so the mechanism cannot be specified further here without going beyond what the sources report.
AOD9604 and musculoskeletal and orthopaedic applications
In the sports-medicine review, AOD-9604 is listed among the peptides marketed for musculoskeletal injury recovery and athletic performance, a use driven by patient demand rather than by an approval pathway [2][3]. A broader review of therapeutic peptides in orthopaedics describes peptides as adjuncts that act on signalling networks including PI3K/Akt, mTOR, MAPK, TGF-beta and AMPK, influencing tissue regeneration and related cellular processes [6]. That review is not specific to AOD9604, and it is cited here only for the general pathway context in which peptide therapeutics in orthopaedics are discussed [6].
AOD9604 and detection in blood matrices
Analytical work on doping control has moved toward detecting small peptides in dried blood spots, and one reported workflow covers 54 prohibited substances using a streamlined, harmonised preparation and detection scheme intended to replace labour-intensive multi-step procedures [4]. AOD9604 is not named in the portion of that report available here, so it is cited only as evidence that small-peptide detection methods in blood matrices are an active area [4].
AOD9604 and the comparison with secretagogues and GHRH analogues
The table below sets out how the review literature groups the agents most often discussed alongside AOD9604, using only the categories those sources provide [1].
| Agent or class | Category in the review literature | Axis level described |
|---|---|---|
| AOD9604 (hGH 176-191) | Growth hormone fragment | Fragment of GH itself [1] |
| Sermorelin, tesamorelin, CJC-1295 with and without DAC | GHRH analogues | Upstream, GHRH receptor route [1] |
| GHRP-2, GHRP-6, hexarelin, ipamorelin | Growth hormone secretagogues | Upstream, secretagogue route [1] |
| IGF-1 analogue | Downstream effector | Post-GH effector [1] |
AOD9604 and the limits of the current evidence
Two constraints should be stated plainly. First, the sources available here are reviews and an analytical methods report; they describe how AOD9604 is classified and marketed, not the outcome of a controlled trial in a defined population [1][2][3][4]. Second, the orthopaedic pathway review that names PI3K/Akt, mTOR, MAPK, TGF-beta and AMPK is a general peptide review and does not attribute those pathways to AOD9604 specifically [6]. Where the evidence block is silent, this page is silent.
AOD9604 and the framing of research-compound marketing
The GH-IGF-1 review notes that peptides in this space are marketed as research compounds while being used in self-administration protocols, and that this creates a gap between the clinical evidence base and actual use [1]. The musculoskeletal review makes the same structural point about unapproved peptides sold direct to patients [2][3]. For laboratory work, that framing matters: it means the published characterisation of AOD9604 is largely classificatory and mechanistic in outline, and any experimental design using the fragment should be built on primary data rather than on marketing claims [1][2][3].
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. https://europepmc.org/article/PMC/PMC13322892
- [2] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. https://doi.org/10.20944/preprints202512.1011.v3
- [3] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. https://doi.org/10.20944/preprints202512.1011.v1
- [4] Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. https://pubmed.ncbi.nlm.nih.gov/42328738/
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. https://pubmed.ncbi.nlm.nih.gov/41966639/
- [6] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://europepmc.org/article/PMC/PMC12753158
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.